VIVUS Regains Compliance with Nasdaq Listing Requirements
September 26, 2018 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address...
VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up
September 24, 2018 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc., (NASDAQ: VVUS), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical...
VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
September 21, 2018 07:30 ET
|
VIVUS, Inc.
-Fundraising event at AT&T Stadium on September 22 supports the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation- CAMPBELL, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc....
VIVUS Announces 1-for-10 Reverse Stock Split
September 10, 2018 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock...
VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia®
August 27, 2018 07:30 ET
|
VIVUS, Inc.
-Retrospective analysis presented at the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management- CAMPBELL, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc....
VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018
August 22, 2018 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...
VIVUS Reports Second Quarter 2018 Financial Results
August 07, 2018 16:05 ET
|
VIVUS, Inc.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed...
VIVUS Appoints Kenneth Suh as President
August 06, 2018 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. ...
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018
July 31, 2018 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of...
VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
July 10, 2018 07:30 ET
|
VIVUS, Inc.
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension- CAMPBELL, Calif., July 10, 2018 (GLOBE NEWSWIRE) --...